Team
An experienced and
complementary team
Jose A. Martinez-Climent
Chief Scientific Officer Founder
- MD and BC in Pediatric Hematology/Oncology
- PhD Cancer Biology and Genetics
30+ years of research in basic and translational oncology
Authors of >100 scientific articles in top hematology and oncology journals (Nature Medicine, Cancer Discovery, Cancer Cell, PNAS, Blood)
Ricardo Pérez Merino
Managing Director
- Executive MBA
- MsC Economics
- Postgraduate Sustainability (Cambridge)
Economist with +25 years of experience, mainly in the PE industry having participated in more than 20 deals and directly involved in more tan 15 board of directors, most of them related to biotech industry
Marta Larrayoz
R&D Director
- Degree in Biology and Biochemistry from the University of Navarra (2006)
- PhD in Biochemistry from the University of Navarra (2011)
Three years as post-doctoral fellow in Hematological-Oncology at the University of Southampton (2013-2016). Marta Larráyoz joined MIMO Biosciences in 2024 as R&D Director, after 10 years working on the development of diverse in vivo models for solid cancers and hematological malignancies, (lymphoma and multiple myeloma). As a translational scientist, her expertise in basic and preclinical oncology is well documented by more than 20 peer-reviewed publications. At MIMO, her main focus is the generation of next-level in vivo platforms that humanize therapeutic targets and immune system cells, aiming to advance translational research.
María José García
Lab Manager
- Degree in Biology from the University of Valencia (2000)
- PhD on Biology from University of Valencia.(2004)
Awarded with a Fulbright grant for Postdoctoral studies at the Lombardi Cancer Center, Georgetown University, Washington D.C and at the Kimmel Cancer Center, Thomas Jefferson University, Philadelphia PA.(2006) More than 20 years of experience as scientist on Cancer Research field reflected on more than 15 relevant scientific publications and up to 15 years planning and performing preclinical research with transgenic models. Associated professor at University of Navarra.
Carmen Vicente
Myeloma Program Director
- Graduated in Biology (2005)
- Ph.D. in Cellular and Molecular Biology from the University of Navarra (2010)
Postdoctoral fellow for 5 years in the Jan Cools Lab at the VIB-KU Leuven, (Belgium). Over 10 years of experience in management and execution of research projects to identify cancer driven mutations/pathways and their targeted opportunities across different hematological malignancies. Actively involved in multiple myeloma translational research during the last years. Co-author of 28 scientific publications in peer reviewed international journals and participation on several national/international competitive funded research projects.
Ion Celay
Lymphoma Program Director
- Biology and Biochemistry Degree from the University of Navarra. (2004 )
- PhD in Health Sciences from the Public University of Navarra. ( 2010)
Postdoctoral researcher in Hemato-Oncology Program at Cima-Universidad de Navarra Research Center. More than 10 years of experience in cellular and molecular biology with high specific expertise in design and execution in pre-clinical trials in Lymphoma . Co-author in more than 15 scientific publications and inventor in one international patent. Team member in 4 international and 7 national competitive projects. Granted with Predoctoral Navarra’s Government grant and and Juan De La Cierva Postdoctoral Fellowship.
Maddalen Jiménez
Project manager
- Degree in Biochemistry from the University of Navarra (2014)
- PhD in Biomedical Research from the University of Navarra. (2019)
Postgraduate Master in Immunologic Research from the Complutense University of Madrid and training course in Oncology and immunology from National Centre of Biotechnology (CNB, Madrid). Since 2015 is responsible for the implementation and management in CIMA and MIMO’s facilities of the preclinical studies with the transgenic and syngeneic models as well as the supervision of the upcoming cohorts due to her high expertise in preclinical experimentation and molecular biology.
Team
